Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Provided By GlobeNewswire
Last update: Aug 7, 2024
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis-
-Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million-
